PhaseBio Pharmaceuticals, Inc. announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. Jonathan will lead PhaseBio?s efforts to build a critical-care focused commercial organization to support the U.S. launch of bentracimab. The company is targeting to submit its Biologics License Agreement with the FDA in mid-2022, which, if approved, could position U.S. launch of bentracimab in early 2023. Jonathan has over 25 years of experience in the biopharmaceuticals industry, including building and leading commercial teams in the United States and the United Kingdom. He joins PhaseBio after 12 years at Genentech where, most recently, he was Vice President and U.S. Head of the company?s thrombolytics franchise. Prior to this role, Jonathan was Lifecycle Leader for the global launch of Kadcyla? and also served as Marketing Director and National Sales Director in the respiratory franchise.